CN105567771A - 一种猪皮小肽螯合物及其制备方法和应用 - Google Patents
一种猪皮小肽螯合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN105567771A CN105567771A CN201610021722.4A CN201610021722A CN105567771A CN 105567771 A CN105567771 A CN 105567771A CN 201610021722 A CN201610021722 A CN 201610021722A CN 105567771 A CN105567771 A CN 105567771A
- Authority
- CN
- China
- Prior art keywords
- pigskin
- gly
- small
- ala
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000013522 chelant Substances 0.000 title abstract description 10
- 230000029663 wound healing Effects 0.000 claims abstract description 17
- 238000006243 chemical reaction Methods 0.000 claims abstract description 9
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 9
- 239000011347 resin Substances 0.000 claims abstract description 5
- 229920005989 resin Polymers 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 238000005507 spraying Methods 0.000 claims description 11
- 239000007901 soft capsule Substances 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000001728 nano-filtration Methods 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 6
- FWBOFUGDKHMVPI-UHFFFAOYSA-K dicopper;2-oxidopropane-1,2,3-tricarboxylate Chemical compound [Cu+2].[Cu+2].[O-]C(=O)CC([O-])(C([O-])=O)CC([O-])=O FWBOFUGDKHMVPI-UHFFFAOYSA-K 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 6
- -1 poly(oxyethylene glycol) Polymers 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 230000000274 adsorptive effect Effects 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 238000010612 desalination reaction Methods 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000012466 permeate Substances 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 235000011478 zinc gluconate Nutrition 0.000 claims description 4
- 239000011670 zinc gluconate Substances 0.000 claims description 4
- 229960000306 zinc gluconate Drugs 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims description 3
- 239000011703 D-panthenol Substances 0.000 claims description 3
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 3
- 235000004866 D-panthenol Nutrition 0.000 claims description 3
- 241000234435 Lilium Species 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 3
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 3
- 235000013871 bee wax Nutrition 0.000 claims description 3
- 239000012166 beeswax Substances 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 229940108925 copper gluconate Drugs 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 229960003949 dexpanthenol Drugs 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 229940119170 jojoba wax Drugs 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 229940057910 shea butter Drugs 0.000 claims description 3
- 229960004418 trolamine Drugs 0.000 claims description 3
- 239000011592 zinc chloride Substances 0.000 claims description 3
- 235000005074 zinc chloride Nutrition 0.000 claims description 3
- 241000270666 Testudines Species 0.000 claims description 2
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000011576 zinc lactate Substances 0.000 claims description 2
- 235000000193 zinc lactate Nutrition 0.000 claims description 2
- 229940050168 zinc lactate Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 208000027418 Wounds and injury Diseases 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 7
- 208000014674 injury Diseases 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000001153 anti-wrinkle effect Effects 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 239000007858 starting material Substances 0.000 abstract 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 28
- 229910052802 copper Inorganic materials 0.000 description 28
- 239000010949 copper Substances 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 27
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 23
- 239000011701 zinc Substances 0.000 description 22
- 229910052725 zinc Inorganic materials 0.000 description 21
- 239000000243 solution Substances 0.000 description 16
- 206010052428 Wound Diseases 0.000 description 14
- 206010040954 Skin wrinkling Diseases 0.000 description 12
- 235000013305 food Nutrition 0.000 description 11
- 108010010803 Gelatin Proteins 0.000 description 10
- 229920000159 gelatin Polymers 0.000 description 10
- 239000008273 gelatin Substances 0.000 description 10
- 235000019322 gelatine Nutrition 0.000 description 10
- 235000011852 gelatine desserts Nutrition 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 239000011573 trace mineral Substances 0.000 description 9
- 235000013619 trace mineral Nutrition 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 241000784728 Lycaena virgaureae Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 208000007502 anemia Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 231100000734 genotoxic potential Toxicity 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002064 Anaemia macrocytic Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010021929 Infertility male Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000530268 Lycaena heteronea Species 0.000 description 1
- 241001124569 Lycaenidae Species 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001062472 Stokellia anisodon Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000017712 cerebellum development Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000014987 copper Nutrition 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 208000036654 deficiency anemia Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000006437 macrocytic anemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 229940032362 superoxide dismutase Drugs 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/985—Skin or skin outgrowth, e.g. hair, nails
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种猪皮小肽螯合物及其制备方法和应用,属生物技术领域。其特征是以猪皮为起始物料,经过酶解、超滤、树脂柱纯化、鳌合反应、干燥得到猪皮小肽螯合物,可加制剂辅料按常规方法制成相应的制剂。本发明采用这种猪皮小肽螯合物能显著促进创口愈合及具有美容祛皱作用,具有无毒副作用、无药害、成本低等优点。
Description
技术领域
本发明涉及生物技术领域,具体涉及一种猪皮小肽螯合物及其制备方法和应用。
背景技术
猪皮始载于《汤液本草》,从古至今,猪皮一直应用于各种相关疾病的治疗,现代临床多用于外科皮肤损伤的治疗。猪皮中的蛋白质含量高达33%,其中胶原蛋白含量为87.8%。猪皮与人体皮肤结构相似,含有丰富的Ⅰ型和Ⅲ型胶原,且与人之间的同源性较牛、鼠好,潜在疾病源少,加之我国是产猪大国,拥有丰富的质优价廉的猪皮资源,人们对从猪皮中提取胶原的研究越来越深入,现以猪皮为原料制备胶原的研究越来越多。
猪皮为常食之物,但作为药物,早有记载。猪皮药用名为猪肤,味甘性凉,有活血止血、补益精血、滋润肌肤、光泽头发、减少皱纹、延缓衰老的作用,因为猪皮中含有大量的胶原蛋白,能减慢机体细胞老化,尤其对阴虚内热,出现咽喉疼痛、低热等症的患者食用更佳。猪肤可以加工煎炼成动物胶,如今市售的“新阿胶”就是用猪皮代替驴皮熬胶而成的“阿胶”。我国最早用猪皮美容与治病的是东汉医圣张仲景,他在《伤寒论》中创制了“猪肤汤”,治少阴病,下利、咽痛、胸满、心烦:猪肤1斤,以水一斗,煮取五升,去滓,加白蜜一升,白粉五合,熬香和合得,温分六服;并且指出,猪肤功能“和血脉,润肌肤”,并有养阴、生津、止渴的功效。
药理研究表明,由猪皮制取的新阿胶有促进骨髓造血功能的作用,另有报道,新阿胶对60Co照射所致造血功能损害小鼠,使其外周血中血红素含量,白细胞数和骨髓有核细胞数均显着高于对照组,其疗效优于阿胶;由新鲜猪皮制取的胶原,在小鼠烧伤后立即局部涂抹,能够促进皮肤粘膜损伤愈合,创面愈合率明显高于对照组,光镜检查,新生上皮下纤维组织的增生现象,成纤维细胞向纤维细胞分化及胶原化的趋势均明显强于对照组,对创而愈合有明显促进作用。
猪皮小肽是运用生物工程和酶解技术从猪皮中提取出来的小分子肽类,其相对分子质量在3KD以下,易透皮吸收,活性更强,溶解性和消化利用率高,安全无副作用、无依赖性。
微量元素与人体健康息息相关,中国微量元素科学研究会会长陈祥友教授指出:“人是由元素组成的,人的生、老、病、死无不与元素平衡有关,当今世界威协人类健康长寿的疑难杂症的突破,有待于元素平衡医学的发展”。微量元素已成功应用于疾病的治疗,研究表明,缺铁会引起贫血,缺铜引起贫血、骨质疏松、冠心病,缺钴会引起巨细胞性贫血、白血病、白内障、口腔溃疡等,缺铬会引起糖尿病、冠心病,缺钼会出现心血管疾病,如心肌坏死冠心病、心绞痛等。
锌是人体必需的微量元素之一,在人体生长发育、生殖遗传、免疫、内分泌等重要生理过程中起着极其重要的作用,被人们冠以“生命之花”、“婚姻和谐素”的美称。锌存在于众多的酶系中,如碳酸酐酶、呼吸酶、乳酸脱氢酸、超氧化物歧化酶、碱性磷酸酶、DNA和RNA聚中酶等中,是核酸、蛋白质、碳水化合物的合成和维生素A利用的必需物质,具有促进生长发育,改善味觉的作用。锌主要存在于动物性食品中,中国家庭中多以植物性食物为主,而且植物性食品中的草酸、植酸、纤维素等严重干扰锌的吸收。近代科学研究证明,缺锌会引发各种病症:比如,锌对生长发育有着促进作用,锌通过参与酶的形成而促进核酸蛋白质合成,影响细胞的生长和***,所以,严重缺锌的儿童就会表现为发育迟缓,矮小症,营养不良,瘦弱,贫血,头发黄。严重缺锌的孕妇由于染色体变形,会导致流产概率的增加,造成习惯性流产;锌可以增强创伤组织再生能力,缺锌就会导致创伤表皮及愈合组织中胶原量减少,创伤不易愈合,所以,锌可以辅助治疗口腔溃疡、胃溃疡、烧伤、创伤以及***痤疮、下肢溃烂、褥疮等病症;锌是维持脑的正常生长和脑功能发育不可缺少的微量元素,缺锌影响脑DNA、RND、蛋白质的形成,就会导致小脑发育迟缓,行为偏离,智力落后,所以,缺锌是导致脑瘫的最主要原因,这一点对孕妇尤其重要;锌还是促进男性***分泌及***形成的重要元素,所以,缺锌也是男性***症、性功能障碍的主要原因。以上种种表明,锌元素对人体的重要,应引起各个人群的重视。
铜元素是一种金属化学元素,也是人体所必须的一种微量元素。人体缺乏铜会引起贫血,毛发异常,骨和动脉异常,以至脑障碍。铜与人体健康关系密切。人体每天都要摄入各种微量元素,铜是人体不能缺少的金属元素之一。成年人体内,1千克体重中,铜含量大约为1.4mg~2.1mg;血液中铜的含量约为1.0mg~1.5mg。这一数量虽小,但它对于维持身体健康和器官的正常运行却不可缺少。这是因为铜元素在机体运行中具有特殊的作用。铜是机体内蛋白质和酶的重要组成部分,许多重要的酶需要微量铜的参与和活化。例如,铜可以催化血红蛋白的合成。研究表明,缺铜会导致血浆胆固醇升高,增加动脉粥样硬化的危险,因而是引发冠状动脉心脏病的重要因素。科学家还发现,营养性贫血、白癫风、骨质疏松症、胃癌及食道癌等疾病的产生也都与人体缺铜有关。严重缺铜和长期边缘性缺铜,还会引发小儿发育不良和一些地方病。铜是人体健康不可缺少的微量营养素,对于血液、中枢神经和免疫***,头发、皮肤和骨骼组织以及脑子和肝、心等内脏的发育和功能有重要影响。铜主要从日常饮食中摄入。世界卫生组织建议,为了维持健康,成人每公斤体重每天应摄入0.03毫克铜。孕妇和婴幼儿应加倍。缺铜会引起各种疾病,可以服用含铜补剂和药丸来加以补充。铜对人体的潜在毒性很轻,只有当摄入量大大超过了正常值时,方会引起胃肠紊乱等不良反应。研究结果表明,当成年男子和女子每天摄入量分别超过12mg和10mg时,会对人体生物化学过程产生轻微的影响。鉴于铜的潜在毒性较低,相反地它却是人体健康不可缺少的元素,世界卫生组织的专家组已作出结论,缺铜的危害远比铜的毒性大得多。除了某些罕见的遗传外,人们主要防止的是缺铜。
某些金属物质是胶原合成所必须得,如铜,当皮肤细胞内铜的含量升高时,胶原蛋白合成增加。不过,铜是一种有毒的金属,而铜肽不仅没有了毒性,而且可促进胶原合成,伤口愈合,有效的抚平皱纹。铜肽(GHK-Cu),又名三胜肽、蓝铜胜肽、甘氨酰-L-组氨酰-L-赖氨酸与铜的络合物,铜肽最初于1973年从人的血浆中分离得到,并于1985年发现其具有伤口修复功能,1999年研究者认为铜肽及其铜复合物可以作为组织重塑的激活剂,其也是一个信号肽,促进伤疤外部大量胶原蛋白集聚物的降解,皮肤正常胶原蛋白的合成、弹力蛋白、蛋白聚糖和葡萄胺聚糖的生成、不同细胞类型的生长速度和迁移、抗炎、抗氧化反应。宾夕法尼亚大学皮肤学教授和该校的强生皮肤研究中心研究表明,将铜肽用于皮肤护理和化妆品中对改善皮肤老化现象很有帮助,含有铜肽的产品可以快速改善皮肤问题,包括减少细纹、皱纹、粗糙、发黄、皮肤松弛和色素沉淀(褐斑)。
猪皮小肽螯合物不仅能更进一步提高小肽的功效,还能提高锌、铜等微量元素的吸收率,而且还能使人体摄入两类物质(小肽和微量元素),各自并协同发挥促进创口愈合和美容保湿的作用。
发明内容
本发明的第一目的在于提供一种猪皮小肽螯合物,本发明的第二目的是提供该猪皮小肽螯合物在制备用于促创口愈合及美容祛皱的食品、保健食品、药品及化妆品中的应用。
本发明目的第一目的是这样实现的:
一种猪皮小肽螯合物,其特征在于采用以下工艺步骤制备:
(1)猪皮小肽的制备:将鲜猪皮切块,加8-12倍量1-3%碳酸钠溶液浸泡6小时,弃去碱液,以水冲洗至近中性,加8-12倍量水匀浆,加水煮沸,待冷至约35~45℃,调节pH值1.0~3.0,加入0.5~2%胃蛋白酶,保温1~3小时,调节pH值7.0~9.0,加入0.5~2%胰蛋白酶,保温3~5小时,煮沸10~15分钟,离心,上清液通过相对分子质量为3KD的超滤膜超滤,透过液加于DA201-C大孔吸附树脂柱上,以水洗脱,弃去水洗液,再以60~90%乙醇洗脱,收集乙醇洗脱液,减压回收乙醇并继续浓缩至60℃相对密度为1.10~1.15的清膏,喷雾干燥(进风温度为180~200℃,出风温度为90~100℃),得到猪皮小肽提取物。猪皮小肽提取物中含有Gln-Pro-Gly-Gly-Gly-Lys-Ala-Ser-Gly-Ala-Gly-Asn-Asp-Ala-Leu-Ser-Gly-Ile-Trp、Val-Ser-Gly-Gly-Leu-Pro-Gly-Leu-Pro-Gly-Ala-Asp-Ala-Leu-Ser-Pro-Gly-Pro-Ala-Leu-Gly-Ala-Gly、Gln-Pro-Gly-Ala-Val-Ser-Gly-Ser-Ala-Ser-Thr-Pro-Gly、Lys-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Ala-Gly-Gly-Thr-Pro-Gly-Ala-Pro-Gln、Arg-Thr-Leu-Pro-Gly-Ser-Pro-Ala-Val-Leu-Leu-Gly-Gly-Gly-Pro-Val-Ala、Pro-Gly-Gly-Ala-Gly-Val-Pro-Ala-Pro-Gly-Ala-Pro-Gln-Gly-Glu六种小肽,总含量为50%~90%。
(2)鳌合反应:将氯化锌(或葡萄糖酸锌,或乳酸锌,或柠檬酸铜,或葡萄糖酸铜,或硫酸铜)溶于蒸馏水配成浓度为10~15mg/ml盐溶液,以稀盐酸调节pH值2~4,按盐溶液与猪皮小肽提取物比例8~10:1比例加入猪皮小肽提取物,搅拌溶解,在温度为50~60℃条件下,螯合反应60~90分钟,用纳滤膜(截留相对分子质量为150~300Da)纳滤除盐,得到猪皮小肽螯合物溶液。
(3)喷雾干燥得螯合物:将猪皮小肽螯合物溶液减压浓缩至60℃相对密度为1.10~1.15,喷雾干燥(进风温度为180~200℃,出风温度为90~100℃),得到猪皮小肽螯合物。
经过上述方法制备的猪皮小肽螯合物,用于制备成下述制剂::
(1)取纯净水,加入卡波姆-980NF,润涨12h,加三乙胺调pH7.5,熟化12h,加入猪皮小肽螯合物,加入尼泊金乙酯,吐温-80、甘油,搅匀,制备成凝胶剂;
(2)按猪皮小肽螯合物:玉米油:蜂蜡:卵磷脂比例为10:36:3:1混合物料,经胶体磨研磨,制备成软胶囊剂;
(3)按猪皮小肽螯合物:聚乙二醇400:丙二醇比例为10:38:2混合物料,经胶体磨研磨,制备成软胶囊剂;
(4)猪皮小肽螯合物,加入常规辅料,制备成口服液、胶囊剂、片剂、颗粒剂;
(5)按以下处方配比,制备成乳霜化妆品:
猪皮小肽螯合物10份,
乳木果油2份,
霍霍巴油2份,
305乳化剂(法国赛比克)2份,
甘油10份,
卡波姆20200.1份,
三乙醇胺0.1份,
D-泛醇1份,
EDTA-2Na0.1份,
水溶性氮酮1份,
香水百合香精0.05份,
纯水71.65份。
但本发明不限于上述剂型。成型工艺所用的常规药剂辅料可以用其他的性质类似的辅料代替,如糖粉、蜂蜜、羧甲基纤维素钠等辅助成型药用辅料;也可与其他药用物质合用,共同达到促创口愈合及美容祛皱的作用。
本发明的第二目的是提供上述猪皮小肽螯合物的用途,其具有促创口愈合及美容祛皱的作用,其可在制备用于促创口愈合及美容祛皱的食品、保健食品、药品及化妆品中应用。
本发明的有益效果是:本发明猪皮小肽螯合物,制备简便,成本低;猪皮小肽与微量元素协同发挥促创口愈合及美容祛皱的作用,同时具有毒副作用小、无耐药性、不易残留等优点,达到绿色食品纯天然的要求,能获得良好的经济效益。
药效试验
为进一步验证本发明猪皮小肽螯合物的促创口愈合及美容祛皱的作用,发明人进行了药效试验考察,试验方法及结果如下:
1.对大鼠皮肤机械创伤愈合的影响
(1)受试药物
猪皮小肽铜螯合物,自制,含猪皮小肽(以总肽量计)71.8%,含铜1.37%。临用前采用CMC-Na溶液配成相应浓度药液。
猪皮小肽锌螯合物,自制,含猪皮小肽(以总肽量计)72.4%,含锌1.40%。临用前采用灭菌蒸馏水配成相应浓度药液。
猪皮小肽,自制,含猪皮小肽(以总肽量计)73.8%。临用前采用灭菌蒸馏水配成相应浓度药液。
葡萄糖酸锌,食品级,锌含量为14.3%。临用前采用灭菌蒸馏水配成相应浓度药液供灌胃。
葡萄糖酸铜,食品级,铜含量为14.1%。临用前采用灭菌蒸馏水配成相应浓度药液供灌胃。
(2)动物及饲养
①动物种属、来源
SD大鼠,雄性,体重180~220g,购自由山东大学试验动物中心提供,动物合格证号:SCXK(鲁)20130004。
②饲养条件
大鼠饲养于独立送风笼具(IVC)中,空气洁净度10000级,实验室温度24±2℃;相对湿度60%~80%;每小时空气交换次数:10-15次/小时;光照周期:12(日)/12(夜)小时。雌雄分开饲养,每笼不超过5只。
饲料:鼠全价颗粒饲料,购自江苏省协同医药生物工程有限责任公司,其质量符合GB14924.1-2001《实验动物配合饲料通用质量标准》。
垫料:灭菌颗粒垫料,购自江苏省协同医药生物工程有限责任公司。
饮水:饮用纯化水,经酸化后自由饮用。
(3)试验方法及结果
动物造模及分组取大鼠60只,按0.4ml/100g腹腔注射1%戊巴比妥钠溶液麻醉,局部剪毛备皮,消毒酒精消毒,于大鼠背部手术剪剪取直径为2cm的圆形切口,剪开皮肤全层,至皮下筋膜,造成机械创伤模型。
将模型大鼠随机分为6组,每组lO只,即猪皮小肽铜螯合物组(100mg/kg)、猪皮小肽锌螯合物组(100mg/kg)、猪皮小肽组(100mg/kg)、柠檬酸铜组(10mg/kg)、葡萄糖酸锌组(10mg/kg)、空白对照组(生理盐水)。
给药方式于模型造好后次日,开始给予药物:各试验组分别于创面涂抹(或覆以)相应药物,空白组于创面涂抹生理盐水,每日2次,连续10d。
创面愈合情况的评价每天观察伤口愈合情况,于第lO天记录创面面积(将创面描记在半透明纸上,再以此为模板,将质地均匀的硬纸片剪成图样大小,以硬纸片重量间接表示创面面积大小,以下式计算:创面愈合率(%)=(开始创伤面积-未愈合创面面积)/开始创伤面积)并处死大鼠,切取部分愈合创面处组织,用***溶液固定并进行组织学检查。
实验结果计量资料以平均值±标准差(±S)表示,两组样本均数间比较用单因素方差分析;记数资料以卡方检验。各实验组的创面愈合率见表1。
表1对大鼠皮肤机械创伤愈合的影响(±S)
注:与空白对照组比较,*P<0.05,**P<0.01。
以上试验结果表明:猪皮小肽铜螯合物组、猪皮小肽锌螯合物组,能明显促进伤口愈合,与空白对照组比较差异有显著性意义(P<0.01);能明显延长小鼠在10℃冷水中的游泳时间,与空白对照组比较差异有显著性意义(P<0.05),猪皮小肽组、柠檬酸铜组、葡萄糖酸锌组与空白对照组比较能促进伤口愈合,且效果猪皮小肽组>柠檬酸铜组>葡萄糖酸锌组,但差异不显著(P>0.05)。说明蚕猪皮小肽螯合物作用明显增强。
具体实施方式
下面列举实施例,进一步说明本发明,各实施例仅用于说明本发明,并不限制本发明:
实施例1
将鲜猪皮切块,加10倍量2%碳酸钠溶液浸泡6小时,弃去碱液,以水冲洗至近中性,加10倍量水匀浆,加热煮沸,待冷至约40℃,调节pH值2.0,加入1%胃蛋白酶,保温1小时,调节pH值8.0,加入1%胰蛋白酶,保温3小时,煮沸15分钟,离心,上清液通过相对分子质量为3KD的超滤膜超滤,透过液加于DA201-C大孔吸附树脂柱上,以水洗脱,弃去水洗液,再以90%乙醇洗脱,收集乙醇洗脱液,减压回收乙醇并继续浓缩至60℃相对密度为1.10~1.15的清膏,喷雾干燥(进风温度为180~200℃,出风温度为90~100℃),得到猪皮小肽提取物。
将柠檬酸铜溶于蒸馏水配成浓度为15mg/ml盐溶液,以稀盐酸调节pH值3,按盐溶液与猪皮小肽提取物比例8:1比例加入猪皮小肽提取物,搅拌溶解,在温度为60℃条件下,螯合反应90分钟,用相对分子质量3KD的纳滤膜纳滤除盐,得到猪皮小肽螯合物溶液,减压浓缩至60℃相对密度为1.10~1.15,喷雾干燥(进风温度为180~200℃,出风温度为90~100℃),得到猪皮小肽螯合物。
实施例2
将鲜猪皮切块,加12倍量3%碳酸钠溶液浸泡6小时,弃去碱液,以水冲洗至近中性,加12倍量水匀浆,加热煮沸,待冷至约45℃,调节pH值1.5,加入2%胃蛋白酶,保温2小时,调节pH值9.0,加入2%胰蛋白酶,保温4小时,煮沸15分钟,离心,上清液通过相对分子质量为3KD的超滤膜超滤,透过液加于DA201-C大孔吸附树脂柱上,以水洗脱,弃去水洗液,再以75%乙醇洗脱,收集乙醇洗脱液,减压回收乙醇并继续浓缩至60℃相对密度为1.10~1.15的清膏,喷雾干燥(进风温度为180~200℃,出风温度为90~100℃),得到猪皮小肽提取物。
将葡萄糖酸锌溶于蒸馏水配成浓度为10mg/ml盐溶液,以稀盐酸调节pH值4,按盐溶液与猪皮小肽提取物比例10:1比例加入猪皮小肽提取物,搅拌溶解,在温度为60℃条件下,螯合反应60分钟,用相对分子质量3KD的纳滤膜纳滤除盐,得到猪皮小肽螯合物溶液,减压浓缩至60℃相对密度为1.10~1.15,喷雾干燥(进风温度为180~200℃,出风温度为90~100℃),得到猪皮小肽螯合物。
实施例3
取实施例1方法所得的猪皮小肽螯合物100g,按猪皮小肽螯合物:玉米油:蜂蜡:卵磷脂比例为10:36:3:1混合物料,经胶体磨研磨30分钟,以明胶、甘油、纯化水、氧化铁黑按100:40:100:1比例制作软胶囊囊皮胶液,控制胶盒温度55±5℃,保温罐40±5℃,喷体温度36±5℃,以压丸机压制软胶囊,每粒内容物重0.50g,18℃~26℃冷风干燥4h(相对湿度为30%~40%)定型,洗丸、干燥、选丸、包装,制备成软胶囊成品。
实施例4
取实施例1方法所得的猪皮小肽螯合物100g,按猪皮小肽螯合物:聚乙二醇400:丙二醇比例为10:38:2混合物料,经胶体磨研磨,以明胶、甘油、纯化水、氧化铁黑按100:40:100:1比例制作软胶囊囊皮胶液,控制胶盒温度55±5℃,保温罐40±5℃,喷体温度36±5℃,以压丸机压制软胶囊,每粒内容物重0.50g,18℃~26℃冷风干燥4h(相对湿度为30%~40%)定型,洗丸、干燥、选丸、包装,制备成软胶囊成品。
实施例5
取实施例2方法所得的猪皮小肽螯合物200g,加淀粉至总量250g,制粒、干燥、整粒,填装胶囊,包装,制备成胶囊成品。
实施例6
取实施例1方法所得的猪皮小肽螯合物,按以下处方配比,制备成乳霜化妆品:
猪皮小肽螯合物10份,
乳木果油2份,
霍霍巴油2份,
305乳化剂(法国赛比克)2份,
甘油10份,
卡波姆20200.1份,
三乙醇胺0.1份,
D-泛醇1份,
EDTA-2Na0.1份,
水溶性氮酮1份,
香水百合香精0.05份,
纯水71.65份。
实施例7
取实施例6所得猪皮小肽螯合物乳霜,进行了试用对照试验,共纳入60例,本品与对照猪皮小肽乳霜组各30例,结果显示:猪皮小肽螯合物乳霜组30例中,肌肤细腻柔滑、有光泽,有微微的紧致感,饱满有弹性,眼角细纹、嘴角纹、法令纹、鱼尾纹变浅。对照组猪皮小肽乳霜30例中,肌肤细腻,有微微的紧致感,眼角细纹、嘴角纹、法令纹、鱼尾纹变浅不明显。两组比较,猪皮小肽螯合物乳霜明显优于猪皮小肽乳霜,猪皮小肽螯合物能从源头直击深入肌底修护损伤,并强化肌肤修护能力,促进肌肤自我新生能力,让肌肤更光滑幼嫩,Q弹莹润,能营养皮肤、舒展皱纹、增强皮肤弹性。
Claims (9)
1.一种猪皮小肽螯合物,其特征在于采用以下工艺步骤制备:
(1)猪皮小肽的制备:将鲜猪皮切块,加8-12倍量1-3%碳酸钠溶液浸泡6小时,弃去碱液,以水冲洗至近中性,加8-12倍量水匀浆,加热煮沸,待冷至约35~45℃,调节pH值1.0~3.0,加入0.5~2%胃蛋白酶,保温1~3小时,调节pH值7.0~9.0,加入0.5~2%胰蛋白酶,保温3~5小时,煮沸10~15分钟,离心,上清液通过相对分子质量为3KD的超滤膜超滤,透过液加于DA201-C大孔吸附树脂柱上,以水洗脱,弃去水洗液,再以60~90%乙醇洗脱,收集乙醇洗脱液,减压回收乙醇并继续浓缩至60℃相对密度为1.10~1.15的清膏,喷雾干燥,得到猪皮小肽提取物;
(2)鳌合反应:将氯化锌溶于蒸馏水配成盐溶液,以稀盐酸调节pH值2~4,加入上述猪皮小肽提取物,搅拌溶解,在温度为50~60℃条件下,螯合反应60~90分钟,用纳滤膜纳滤除盐,得到猪皮小肽螯合物溶液;
(3)喷雾干燥得螯合物:将猪皮小肽螯合物溶液减压浓缩至60℃相对密度为1.10~1.15,喷雾干燥,得到猪皮小肽螯合物。
2.根据权利要求1所述的猪皮小肽螯合物,其特征在于步骤(1)所述猪皮小肽提取物中含有Gln-Pro-Gly-Gly-Gly-Lys-Ala-Ser-Gly-Ala-Gly-Asn-Asp-Ala-Leu-Ser-Gly-Ile-Trp、Val-Ser-Gly-Gly-Leu-Pro-Gly-Leu-Pro-Gly-Ala-Asp-Ala-Leu-Ser-Pro-Gly-Pro-Ala-Leu-Gly-Ala-Gly、Lys-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Ala-Gly-Gly-Thr-Pro-Gly-Ala-Pro-Gln、Arg-Thr-Leu-Pro-Gly-Ser-Pro-Ala-Val-Leu-Leu-Gly-Gly-Gly-Pro-Val-Ala、Pro-Gly-Gly-Ala-Gly-Val-Pro-Ala-Pro-Gly-Ala-Pro-Gln-Gly-Glu、Gln-Pro-Gly-Ala-Val-Ser-Gly-Ser-Ala-Ser-Thr-Pro-Gly六种小肽,总含量为50%~90%。
3.根据权利要求1所述的猪皮小肽螯合物,其特征在于步骤(2)所述氯化锌可以用葡萄糖酸锌、乳酸锌、柠檬酸铜、葡萄糖酸铜、硫酸铜代替。
4.根据权利要求1所述的猪皮小肽螯合物,其特征在于步骤(2)所述盐溶液的浓度为10~15mg/ml。
5.根据权利要求1所述的猪皮小肽螯合物,其特征在于步骤(2)所述盐溶液与猪皮小肽提取物比例为8~10:1。
6.根据权利要求1所述的猪皮小肽螯合物,其特征在于步骤(2)所述纳滤膜的截留相对分子质量为150~300Da。
7.根据权利要求1所述的猪皮小肽螯合物,其特征在于步骤(1)与(3)所述喷雾干燥进风温度为180~200℃,出风温度为90~100℃。
8.根据权利要求1所述的猪皮小肽螯合物,其特征在于制备成下述制剂:
(1)取纯净水,加入卡波姆-980NF,润涨12h,加三乙胺调pH7.5,熟化12h,加入猪皮小肽螯合物,加入尼泊金乙酯,吐温-80、甘油,搅匀,制备成凝胶剂;
(2)按猪皮小肽螯合物:玉米油:蜂蜡:卵磷脂比例为10:36:3:1混合物料,经胶体磨研磨,制备成软胶囊剂;
(3)按猪皮小肽螯合物:聚乙二醇400:丙二醇比例为10:38:2混合物料,经胶体磨研磨,制备成软胶囊剂;
(4)猪皮小肽螯合物,加入常规辅料,制备成口服液、胶囊剂、片剂、颗粒剂;
(5)按以下处方配比,制备成乳霜化妆品:
猪皮小肽螯合物10份,
乳木果油2份,
霍霍巴油2份,
305乳化剂(法国赛比克)2份,
甘油10份,
卡波姆20200.1份,
三乙醇胺0.1份,
D-泛醇1份,
EDTA-2Na0.1份,
水溶性氮酮1份,
香水百合香精0.05份,
纯水71.65份。
9.权利要求1所述的猪皮小肽螯合物用于促创口愈合及美容祛皱。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610021722.4A CN105567771A (zh) | 2016-01-14 | 2016-01-14 | 一种猪皮小肽螯合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610021722.4A CN105567771A (zh) | 2016-01-14 | 2016-01-14 | 一种猪皮小肽螯合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105567771A true CN105567771A (zh) | 2016-05-11 |
Family
ID=55878389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610021722.4A Pending CN105567771A (zh) | 2016-01-14 | 2016-01-14 | 一种猪皮小肽螯合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105567771A (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105925652A (zh) * | 2016-07-15 | 2016-09-07 | 安徽精准医疗产业研究院有限公司 | 一种仿生酶解生产小肽的方法 |
CN105962106A (zh) * | 2016-07-15 | 2016-09-28 | 安徽精准医疗产业研究院有限公司 | 利用仿生酶解技术生产阿胶小肽的方法及其应用 |
CN106975068A (zh) * | 2017-04-28 | 2017-07-25 | 安徽生物肽产业研究院有限公司 | 一种猪皮胶原小肽有效部位组合物 |
CN107126555A (zh) * | 2017-04-28 | 2017-09-05 | 安徽生物肽产业研究院有限公司 | 一种促进创面愈合的猪皮胶原小肽有效部位组合物 |
CN107279458A (zh) * | 2017-07-13 | 2017-10-24 | 安徽生物肽产业研究院有限公司 | 一种具有增强机体免疫力的富锌豌豆小肽及其制备方法 |
CN112813123A (zh) * | 2020-12-04 | 2021-05-18 | 苏州艾博迈尔新材料有限公司 | 一种含铜络合物的制备方法 |
CN113980122A (zh) * | 2021-10-28 | 2022-01-28 | 滨州医学院 | 猪皮胶原肽-亚铁螯合物的制备方法及用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102827910A (zh) * | 2012-08-02 | 2012-12-19 | 广州市博善生物饲料有限公司 | 一种小肽螯合铜复合物的制备方法与应用 |
CN102827909A (zh) * | 2012-08-02 | 2012-12-19 | 广州市博善生物饲料有限公司 | 一种小肽螯合锌复合物的制备方法与应用 |
-
2016
- 2016-01-14 CN CN201610021722.4A patent/CN105567771A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102827910A (zh) * | 2012-08-02 | 2012-12-19 | 广州市博善生物饲料有限公司 | 一种小肽螯合铜复合物的制备方法与应用 |
CN102827909A (zh) * | 2012-08-02 | 2012-12-19 | 广州市博善生物饲料有限公司 | 一种小肽螯合锌复合物的制备方法与应用 |
Non-Patent Citations (3)
Title |
---|
刘永等: "罗非鱼鳞胶原蛋白肽锌螯合物制备工艺优化", 《食品与工业发酵》 * |
刘长龙: "猪皮促创面愈合活性肽的制备分离及鉴定研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
段绍斌等: "《临床疾病营养学》", 31 January 2014, 北京:科学技术文献出版社 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105925652A (zh) * | 2016-07-15 | 2016-09-07 | 安徽精准医疗产业研究院有限公司 | 一种仿生酶解生产小肽的方法 |
CN105962106A (zh) * | 2016-07-15 | 2016-09-28 | 安徽精准医疗产业研究院有限公司 | 利用仿生酶解技术生产阿胶小肽的方法及其应用 |
CN106975068A (zh) * | 2017-04-28 | 2017-07-25 | 安徽生物肽产业研究院有限公司 | 一种猪皮胶原小肽有效部位组合物 |
CN107126555A (zh) * | 2017-04-28 | 2017-09-05 | 安徽生物肽产业研究院有限公司 | 一种促进创面愈合的猪皮胶原小肽有效部位组合物 |
CN107279458A (zh) * | 2017-07-13 | 2017-10-24 | 安徽生物肽产业研究院有限公司 | 一种具有增强机体免疫力的富锌豌豆小肽及其制备方法 |
CN112813123A (zh) * | 2020-12-04 | 2021-05-18 | 苏州艾博迈尔新材料有限公司 | 一种含铜络合物的制备方法 |
CN113980122A (zh) * | 2021-10-28 | 2022-01-28 | 滨州医学院 | 猪皮胶原肽-亚铁螯合物的制备方法及用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105567771A (zh) | 一种猪皮小肽螯合物及其制备方法和应用 | |
TWI516280B (zh) | 紅藜萃取物用於製備促進膠原蛋白生成及抗皮膚老化之組合物之用途 | |
CN106343147A (zh) | 一种玫瑰胶原蛋白肽粉的制备方法 | |
CN106418545A (zh) | 一种营养均衡的功能性食品 | |
CN102742658B (zh) | 一种养颜美容羊奶片及其制备方法 | |
CN105380271A (zh) | 无添加剂全籽粒绿豆复合营养粉及其生产方法 | |
JP4132635B2 (ja) | 未失活酵素強化組成物 | |
CN103976202B (zh) | 一种可食用胶原蛋白果冻及其制备方法 | |
CN105661554A (zh) | 一种提高免疫力的蚕蛹小肽螯合物及其制备方法 | |
CN101152239A (zh) | 一种雄蜂蛹冻干粉冲剂及胶囊的制备工艺 | |
CN102659917A (zh) | 一种从松花粉中分离制备粗蛋白及酶解肽类的方法 | |
KR20090124815A (ko) | 화장료 조성물 및 그 제조방법 | |
KR20080090808A (ko) | 피부미용을 위한 건강보조식품의 조성물 | |
CN109730222A (zh) | 酵素复合液及其保健饮料 | |
CN100506085C (zh) | 一种能够提高产妇免疫力的红糖保健品 | |
CN103750096A (zh) | 富含植物精华的蜂胶蜜及其制备方法 | |
CN103919229B (zh) | 一种安眠定神保健速溶粉 | |
CN102719337A (zh) | 木耳保健啤酒 | |
CN113648347A (zh) | 含莲子外泌体的卵巢保养的组合物及其制备方法 | |
CN105995980A (zh) | 一种具有体重管理作用的组合物及其制备方法 | |
CN102948733B (zh) | 一种特殊食用生命营养液的生产方法和配方 | |
CN105995971A (zh) | 一种促进糖尿病康复的营养流食及其制备方法 | |
CN106376792A (zh) | 一种黑木耳清肺粉及其制备方法 | |
CN108813500A (zh) | 具有补中益气、养血安神和调节人体机能的养生蜂蜜膏 | |
CN104187264B (zh) | 一种提高人体免疫力的营养组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180905 Address after: 251200 Shandong Dezhou Yucheng high tech Zone Vocational Education Center Innovation and entrepreneurship Building 8 floors South Building Applicant after: Shandong Yu Ze Pharmaceutical Technology Co., Ltd. Address before: 241000 Room 201, B01 building, Da Long Fang Culture Park, Jinghu District, Wuhu, Anhui (77) Applicant before: ANHUI BIOLOGICAL PEPTIDE INDUSTRY RESEARCH INSTITUTE |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160511 |